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Abstract

Introduction: We sought to describe the incidence, risk factors, and survival outcomes associated with pathologic upstaging from non-muscle invasive bladder cancer (NMIBC) to muscle invasive bladder cancer (MIBC)
after robot-assisted radical cystectomy (RARC).
Methods: We reviewed the International Robotic Cystectomy Consortium database between 2004 and 2020.
Upstaging was defined as ‡pT2 or pathologic node positive (pN+) at final pathology analysis from clinical <T2N0M0.
Descriptive statistics were used to summarize data. Cochran–Armitage test was used to depict upstaging trend over
time. Multivariate regression models were used to depict variables associated with upstaging. Kaplan–Meier curves
were used to describe disease-specific survival (DSS), recurrence-free survival (RFS), and overall survival (OS).
Results: A total of 463 patients underwent RARC for NMIBC. Upstaging occurred in 145 (31%) patients.
Upstaged patients were older (70 vs 67 years, p < 0.01), more likely to have American Society of Anesthesiologists (ASA) score (‡3; 55% vs 44%, p = 0.04), and had higher rate of preoperative hydronephrosis (26% vs
10%, p < 0.01). They were more likely to have positive surgical margins (10% vs 3%, p = 0.01), recurrences
(28% vs 9%, p < 0.01), and to receive adjuvant/salvage treatment (26% vs 3%, p < 0.01). On multivariate
analysis, upstaging was associated with older age (odds ratio [OR] 1.04; confidence interval [CI] 1.01–1.07,
p < 0.01), cT1 vs cTis (OR 4.25; CI 1.57–11.48, p < 0.01), cT1 vs cTa (OR 2.92; CI 1.40–6.06, p < 0.01), and
preoperative hydronephrosis (OR 3.18; CI 1.60–6.32, p < 0.01). Upstaged patients had worse 5-year RFS (53%
vs 85%, log rank p < 0.01), DSS (66% vs 93%, log rank p < 0.01), and OS (49% vs 74%, log rank p < 0.01). The
rate of upstaging did not significantly change over time (38% in 2004 to 27% in 2019, p = 0.17).
Conclusion: Upstaging to MIBC occurred in a significant proportion of patients after RARC for NMIBC and
was associated with worse survival outcomes. Older patients, those with cT1 disease and hydronephrosis were
more likely to upstage.
Keywords: upstaging, robot-assisted, radical cystectomy, non-muscle invasive, bladder cancer, pathologic
discrepancy
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on-muscle invasive bladder cancer (NMIBC) represents more than two-thirds of patients found with bladder cancer, for whom transurethral resection of bladder tumor
(TURBT), with or without intravesical adjuvant therapy is the
mainstay of treatment.1 Radical cystectomy (RC) is usually reserved for patients who fail intravesical therapy, or those at
highest risk of recurrence and progression.2 Importantly, patients with de novo muscle invasive bladder cancer (MIBC)
treated with RC and pelvic lymph node dissection have better outcomes compared with those who develop secondary
MIBC.3 Ge and colleagues performed a comprehensive systematic review on the subject and reported a pooled hazard
ratio (HR): 1.29, 95% confidence interval [CI]: 1.07 to 1.56,
p = 0.008 for secondary MIBC.3 Therefore, the current American Urological Association guidelines suggest offering
cystectomy for NMIBC in case of (1) Ta disease for which
bladder-sparing modalities have failed, (2) persistent highgrade T1 disease, T1 tumors with Carcinoma in Situ (CIS),
variant histology or lymphovascular invasion, and (3) those
with persistent or recurrent disease within 1 year after treatment with two induction cycles of Bacillus Calmette-Guérin
(BCG) or BCG maintenance.2
Clinical staging of bladder cancer comprises a combination of physical examination, including bimanual examination, axial abdominal/chest imaging and TURBT. However,
multiple studies have shown a discrepancy in up to 50%
of cases between clinical and pathologic staging, mostly
understaging.4–6 In this context, we analyzed the data from
International Robotic Cystectomy Consortium (IRCC) database to identify the incidence, risk factors, and survival outcomes associated with pathologic upstaging from NMIBC
to MIBC after robot-assisted radical cystectomy (RARC).

FIG. 1.

A retrospective review of the prospectively maintained
IRCC database (I-97906; 3469 RARCs, from 28 institutions
in 14 countries) was performed. Patients who underwent
RARC for NMIBC (<cT2N0M0) were identified (n = 463).
Patients were divided into those who upstaged from NMIBC
(Ta/CIS/T1) to MIBC (‡pT2 or pathologic node positive
[pN+] after RARC) vs those who did not. Data were reviewed for demographics, preoperative, operative, postoperative, and pathologic outcomes. Descriptive statistics were
used to summarize the data. Trend for upstaging over time were
assessed using Cochran–Armitage test. Multivariate logistic
regression models were used to assess variables associated
with upstaging. Kaplan–Meier curves were used to depict
recurrence-free survival (RFS), disease-specific survival
(DSS), and overall survival (OS). Multivariate Cox regression
models were used to analyze factors associated with RFS,
DSS, and OS. All tests were double sided with significance set
at £0.05. Statistical analysis was performed using SAS software (version 9.4; SAS Institute, Inc., Cary, NC).
Results

A total of 463 patients underwent RARC for NMIBC. The
median follow-up (interquartile range [IQR]) after cystectomy was 29 (IQR 10–57) months. Upstaging occurred in 145
(31%) patients (pT2 in 49%, pT3 in 34% and pT4 in 12% of
patients, and 5% upstaged because of pN+). Trend test
showed a decrease from 38% in 2004 to 27% in 2019 for
upstaging; however, this was not statistically significant
( p = 0.17) (Fig. 1). Upstaged patients were older (70 vs
67 years, p < 0.01), had higher median Charlson comorbidity
index (CCI) score (5 vs 4, p < 0.01), had American Society
of Anesthesiologists (ASA) score ‡3 more frequently (55%

Trend plot for upstaging over the years ( p = 0.17).
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vs 44%, p = 0.04), had higher rates of preoperative hydronephrosis (26% vs 10%, p < 0.01), and lower preoperative
median glomerular filtration rate (GFR; 71 mL/minute vs
78 mL/minute, p = 0.01) compared with patients who did not
upstage. The presence of overall variant histology did not
differ significantly between the two groups (15% vs 14%,
p = 0.67). However, patients who upstaged showed squamous
(10% vs 0.3%, p < 0.01), plasmacytoid (2% vs 0%, p = 0.03),
and sarcomatoid (4% vs 0%, p < 0.01) features more frequently (Table 1). Upstaged patient had shorter operative time
(6 vs 6.3 hours, p < 0.01), higher positive soft tissue surgical
margins at RARC (10% vs 3%, p = 0.01) and were more likely
to receive adjuvant/salvage chemotherapy (26% vs 3%,
p < 0.01). Upstaged patients relapsed more frequently (28%
vs 9%, p < 0.01), both local (12% vs 4%, p < 0.01) and distant
(22% vs 4%, p < 0.01) (Table 2).
On multivariate logistic regression analyses, upstaging
was significantly associated with age (odds ratio [OR] 1.04;
95% CI 1.01–1.07, p < 0.01), cT1 vs cTa (OR 2.92; 95% CI
1.40–6.06, p < 0.01), cT1 vs cTis (OR 4.25; 95% CI 1.57–
11.48, p < 0.01), and preoperative hydronephrosis (OR 3.18;
95% CI 1.60–6.32, p < 0.01) (Table 3).

Upstaged patients had worse 5-year RFS (53% vs 85%, log
rank p < 0.01), DSS (66% vs 93%, log rank p < 0.01), and OS
(49% vs 74%, log rank p < 0.01) (Figs. 2–4). Multivariate
Cox regression analysis showed that upstaging associated
with worse RFS (HR 4.10, 95% CI 2.50–6.70, p < 0.01), DSS
(HR 6.71, 95% CI 3.31–13.60, p < 0.01), and OS (HR 1.71,
95% CI 1.08–2.73, p = 0.02). OS was also associated with age
(HR 1.04, 95% CI 1.01–1.06, p < 0.01), higher ASA score
(HR 1.74, 95% CI 1.06–2.86, p = 0.03), and length of intensive care unit (ICU) stay (HR 1.17, 95% CI 1.07–1.27,
p < 0.01) (Table 4).
Discussion

Discordance between clinical stage (as determined by
cystoscopy, TURBT, examination under anesthesia and imaging) and pathologic stage in bladder cancer has been
previously documented.4–6 Prior studies showed that these
patients have worse survival outcomes compared with those
who have de novo MIBC.3 This has spurred efforts to
improve clinical staging by incorporation of second look
TURBT in patients who lacked sampling of the detrusor
muscle in the initial TURBT, when there is concern about

Table 1. Demographics, Clinical Characteristics, and Preoperative Characteristics
of the Upstaged Patients

No. of patients (%)
Age at cystectomy, median (IQR)
Gender, male n (%)
Caucasians, n (%)
African Americans, n (%)
Other races, n (%)
Body mass index, kg/m2, mean (SD)
ASA score ‡3, mean (%)
Smoking (ever), n (%)
Smoking (current), n (%)
Charlson comorbidity index, median (IQR)
GFR, median (IQR)
Hydronephrosis, n (%)
Prior abdominal/pelvic surgery, n (%)
Prior irradiation, n (%)
Clinical T stage, cTa, n (%)
Clinical T stage, cTis, n (%)
Clinical T stage, cT1, n (%)
Grade 1, n (%)
Grade 2, n (%)
Grade 3, n (%)
Multifocal disease, n (%)
Preoperative histology
Pure urothelial histology at TURBT, n (%)
Variant histology at TURBT, n (%)
Postoperative histology
Adenocarcinoma, n (%)
Squamous, n (%)
Micropapillary, n (%)
Plasmacytoid, n (%)
Sarcomatoid, n (%)
Small cell, n (%)
Nested, n (%)
Neuroendocrine, n (%)

No upstaging

Upstaged to MIBC

All

318 (69)
67 (60–74)
251 (79)
302 (95)
8 (3)
7 (2)
28 – 6
120 (44)
119 (66)
36 (20)
4 (3–6)
78 (62–90)
19 (10)
125 (57)
11 (5)
72 (23)
67 (21)
179 (56)
26 (10)
12 (4)
231 (86)
54 (31)

145 (31)
70 (62–76)
121 (83)
138 (95)
6 (4)
1 (1)
28 – 5
69 (55)
63 (70)
13 (14)
5 (3–7)
71 (55–85)
26 (26)
50 (49)
8 (8)
16 (11)
12 (8)
117 (81)
4 (3)
7 (6)
106 (91)
29 (39)

463 (100)
68 (61–75)
372 (81)
440 (95)
14 (3)
8 (2)
28 – 6
189 (47)
182 (68)
49 (18)
4 (3–6)
75 (57–88)
45 (15)
175 (54)
19 (6)
88 (19)
79 (17)
296 (64)
30 (8)
19 (5)
337 (87)
83 (33)

274 (86)
44 (14)

121 (85)
22 (15)

395 (86)
66 (14)

27
1
16
0
0
1
0
1

(8)
(0.31)
(5)
(0)
(0)
(0.31)
(0)
(0.31)

14
14
6
3
6
2
1
0

(10)
(10)
(4)
(2)
(4)
(1)
(1)
(0)

41
15
22
3
6
3
1
1

(9)
(3)
(5)
(1)
(1)
(1)
(0.22)
(0.22)

p
<0.01
0.31
0.35
0.17
0.04
0.58
0.32
<0.01
0.01
<0.01
0.19
0.45
<0.01
0.08
0.31
0.67
0.73
<0.01
0.82
0.03
<0.01
0.23
0.31
1

Bolded values are statistically significant.
ASA = American Society of Anesthesiologists; GFR = glomerular filtration rate; IQR = interquartile range; MIBC = muscle invasive
bladder cancer; SD = standard deviation; TURBT = transurethral resection of bladder tumor.
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Table 2. Operative and Pathologic Characteristics of the Upstaged Patients
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No upstaging
Duration between diagnosis and cystectomy, days (IQR)
Diversion approach, intracorporeal, n (%)
Type of diversion, neobladder, n (%)
Operative time, hours, median (IQR)
Blood transfusion, n (%)
Inpatient stay, median (IQR) (days)
Return to operating room (OR) within 30 days, n (%)
Any complication, n (%)
High grade complication, n (%)
90-Day mortality rate, n (%)
Adjuvant/salvage therapy, n (%)
Pathologic T stage, pT2, n (%)
Pathologic T stage, pT3, n (%)
Pathologic T stage, pT4, n (%)
Pathologic node positive, n (%)
Positive surgical margins, n (%)
Any recurrence, n (%)
Any distal recurrence, n (%)
Any local recurrence, n (%)

265
213
72
6.3
13
8
20
204
90
7
7

9
28
14
14

(67–645)
(68)
(23)
(5.3–7.8)
(4)
(6–13)
(6)
(64)
(28)
(2)
(3)
—
—
—
—
(3)
(9)
(4)
(4)

Upstaged to MIBC
130
97
21
6
6
8
7
102
51
4
32
71
49
17
51
12
41
32
17

(57–624)
(68)
(15)
(5–6.9)
(4)
(6–13)
(5)
(70)
(35)
(3)
(26)
(49)
(34)
(12)
(35)
(10)
(28)
(22)
(12)

All
210
310
93
6.2
19
8
27
306
141
11
39
71
49
17
51
21
69
46
31

(62–636)
(68)
(20)
(5.1–7.4)
(4)
(6–13)
(6)
(66)
(30)
(2)
(10)
(15)
(11)
(4)
(11)
(5)
(15)
(10)
(7)

p
0.14
0.91
0.05
<0.01
1.00
0.08
0.67
0.21
0.16
0.75
<0.01
—
—
—
—
0.01
<0.01
<0.01
<0.01

Bolded values are statistically significant.

incomplete resection (especially in multiple or large tumors),
presence of T1 or high-grade disease.2 Although second
TURBT has improved staging, still 20% to 40% of patients
exhibit pathologic upstaging at radical cystectomy.7–9 The
presence of variant histology at TURBT has been also associated with upstaging at the time of radical cystectomy,
and most guidelines recommend early cystectomy for these
patients.2,9 In this study, the presence of overall variant histologies did not significantly differ among patients who upstaged vs those who did not, but there was a higher prevalence
of squamous, plasmacytoid, and sarcomatoid features among
patients who upstaged. However, we did not confirm a significant association between upstaging and variant histology
on multivariate analysis, which may be related to the small
number of patients with variant histology in this study.
We found that 31% of NMIBC patients were upstaged to
MIBC disease after RARC. Multiple studies that examined
upstaging in open RC cohorts have reported rates from 15%
to 46%.7–10 The largest study from Svatek and coworkers
evaluated 592 patients between 1979 and 2008, and demonstrated 46% of patients were upstaged from NMIBC to MIBC
post-RC.6 The higher rate of upstaging could be explained by
the earlier era, where second look TURBT was not a common
practice, improvement in imaging modalities over time and
improved adherence to treatment guidelines. We looked at the
trend for upstaging between years 2004 and 2020. There was

Table 3. Multivariate Logistic Analysis
for Predictors of Upstaging

Age
Preoperative
hydronephrosis
Clinical stage T1 vs Ta
Clinical stage T1 vs Tis

Odds
ratio

95% Confidence
interval

p

1.04
3.18

1.01–1.07
1.60–6.32

<0.01
<0.01

2.92
4.25

1.40–6.06
1.57–11.48

<0.01
<0.01

an overall decrease (although statistically nonsignificant) in
the rate of upstaging from 38% to 27% in this time period,
possibly reflecting the influence of change in practice guidelines, more sensitive imaging and offering RC upfront to patients with refractory NMIBC more frequently.11,12
In our study, upstaged patients were likely to be older and
had worse underlying health status as evidenced by higher CCI
and ASA scores. In the past, higher CCI has been shown to
correspond with worse prognosis in other cancers.13 It may
delay definitive treatment (RC) from being offered to patients.
Also, the prevalence of preoperative hydronephrosis was higher
in the upstaged group. Gray and colleagues have previously
demonstrated that hydronephrosis is independently associated
with upstaging in bladder cancer patients.14 This may be a
contributing factor to the decreased GFR in the upstaged cohort. We found higher rate of positive soft tissue surgical
margins (10%) in upstaged patients compared with 3% in those
who did not upstage. Previous study by Fritsche and associates
identified positive margins in 7% of upstaged patients.15
Furthermore, it has been suggested that upstaging in patients
may be used as an indicator for need of adjuvant chemotherapy.15 In agreement with this, we found that upstaged patients
were more likely to receive adjuvant/salvage chemotherapy
compared with those who retained their preoperative stage.
On multivariate analysis we found age, preoperative
hydronephrosis, and cT1 to be associated with upstaging.
Previously, Gray and colleagues examined the National
Cancer Database (NCDB) and found age and preoperative
hydronephrosis to be associated with upstaging.14 The link
between older age and upstaging has been attributed to more
aggressive cancer biology and inadequate staging in these patients.14,16 Hydronephrosis in bladder cancer patients occurs
because of tumors at ureteral orifice, secondary ureteral tumors
or compression of the ureter. Tumors resulting in hydronephrosis maybe located in difficult to access areas and thus
missed or inadequately sampled. Multiple studies have shown
association between hydronephrosis and advanced tumors
eventually resulting in worse prognosis.17,18 Similarly, cT1
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FIG. 2. Kaplan–Meier curves showing recurrence-free survival (log rank p < 0.01).
disease is a known risk factor for upstaging, especially when
high grade.15,19 Female gender, variant histology, higher grade,
and lymphovascular invasion are some of the other factors that
have been associated with upstaging in the past.9,14,20
The time elapsed between first diagnosis of bladder cancer
and RARC could be reasonably expected to correlate with
progression and upstaging, but we found no such association.
Turker and colleagues found no effect of time elapsed between last TURBT and cystectomy on upstaging, but there
could be a limitation because of the smaller sample size
(n = 366 with available data).9 Although the interval between
TURBT and RARC may influence upstaging, these data were
unfortunately not captured in our database for all patients.
Accurate staging for NMIBC is associated with better survival outcomes.21,22 In our study, upstaging was the sole pre-

FIG. 3.

dictor of RFS and DSS. In an earlier study, Guzzo and coworkers
had shown that upstaging after RC was associated with worse
RFS at the 5-year interval (61% vs 74%, p = 0.04), this difference
was further pronounced in those treated with Bacillus CalmetteGuerin therapy (86% vs 57%).23 Upstaged patients had lower
OS as well. Although multiple factors such as age, preoperative
comorbidities and postoperative course were associated with
OS, upstaging continued to be an independent predictor of decreased OS. The worse survival outcomes for upstaged patients
make a case for more aggressive staging during TURBT, highquality cross-sectional imaging immediately before cystectomy
or offering them an early cystectomy. Alternately, these patients
may benefit from more intensive surveillance and follow-up.
Considering the significance of upstaging on oncologic outcomes and survival, multiple efforts are ongoing to identify the

Kaplan–Meier curves comparing disease-specific survival (log rank p < 0.01).
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FIG. 4.

Kaplan–Meier curves comparing overall survival (log rank p < 0.01).

predictors of upstaging and/or treatment response in NMIBC.
Although traditionally there was emphasis on histology report
and imaging to identify patients at increased risk of upstaging or
recurrence, newer methods involving genotypic analysis are
being studied currently. Awadalla and coworkers compared the
circulating tumor cells gene expression of bladder cancerrelated genes in T1 grade 3 patients and found strong correlation
to recurrence and progression.24 Clinton and colleagues utilized
genomic profiling to identify patients that may benefit from
neoadjuvant chemotherapy.25 Similarly, Lotan and coworkers
used molecular subtyping to demonstrate lower rate of pathologic upstaging in luminal tumors.26 These novel approaches
maybe the key classifiers of the future as 49% of the upstaged
patients are negative for traditional clinical risk factors.27
To our knowledge, this is the first study to examine the
pattern of upstaging in RARC patients. We recognize the
limitations of our study, including the smaller sample size
and retrospective nature. Also, some critical variables such as
lymphovascular invasion, number of TURBTs and intravesical treatment received were not captured in our database.
We did not find a significant association between variant

histology and upstaging, likely because of small number of
patients with variant histology in this study. Finally, despite
their ease of application, availability, and cost benefits, it can
be reasonably expected that predictors of upstaging will
move from histologic, imaging, or demographic parameters
toward molecular subtyping and genomic analysis in the
coming years24–26
Conclusion

Upstaging to MIBC occurs in a significant proportion of
patients after RARC and has been associated with worse
survival outcomes. There is a need to develop reliable clinical and molecular measures to identify patients at a risk of
upstaging.
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ASA ¼ American Society of Anesthesiologists
CCI ¼ Charlson comorbidity index
CI ¼ confidence interval
DSS ¼ disease-specific survival
GFR ¼ glomerular filtration rate
HR ¼ hazard ratio
ICU ¼ intensive care unit
IQR ¼ interquartile range
IRCC ¼ International Robotic Cystectomy Consortium
MIBC ¼ muscle invasive bladder cancer
NMIBC ¼ non-muscle invasive bladder cancer
OR ¼ odds ratio
OS ¼ overall survival
pN+ ¼ pathologic node positive
RARC ¼ robot-assisted radical cystectomy
RFS ¼ recurrence-free survival
SD ¼ standard deviation
TURBT ¼ transurethral resection of bladder tumor.

